1. Home
  2. / Science and Technology
  3. / Slimming pen still unapproved becomes a global topic after study indicates weight loss similar to bariatric surgery, while clandestine versions of retatrutide appear at the border.
Reading time 3 min of reading Comments 0 comments

Slimming pen still unapproved becomes a global topic after study indicates weight loss similar to bariatric surgery, while clandestine versions of retatrutide appear at the border.

Written by Viviane Alves
Published on 08/06/2026 at 22:38
Be the first to react!
React to this article

Research published in The Lancet shows that retatrutide reduced up to 28.3% of weight in adults with type 2 diabetes, but the product still lacks health approval.

A new study on retatrutide drew worldwide attention by indicating an average weight loss of up to 28.3% of body weight in adults with type 2 diabetes.

The study was published in the scientific journal The Lancet this Saturday, 6, and reinforced data released by Eli Lilly, the company responsible for developing the substance.

This result placed the new weekly injection at the center of the debate on obesity, type 2 diabetes, and high-potency medications.

The observed loss was considered close to that obtained in bariatric surgery, although the product still depends on final studies and regulatory approval.

Technical research reveals how retatrutide works

Retatrutide belongs to the same family as the so-called weight-loss pens, such as Ozempic and Mounjaro.

However, the substance acts on three different hormones at the same time, while other medications act on one or two mechanisms.

For this reason, specialists describe the molecule as a triple-action therapy.

The differential lies in the glucagon receptor, which can stimulate greater energy expenditure during treatment.

Retatrutide also mimics hormones released by the intestine after meals.

These hormones signal satiety to the brain and help the pancreas control insulin.

Study shows significant weight loss

In the study, 930 adults with type 2 diabetes received weekly doses of retatrutide or placebo for up to 80 weeks.

Participants who used the highest dose lost, on average, 28.3% of body weight.

This result was more than four times higher than that observed in the placebo group.

More than 65% of these patients no longer met the criteria for obesity by BMI.

The drop in blood sugar levels was also more than double that recorded in the control group.

Data indicates effects on sleep apnea and osteoarthritis

The research also brought results on sleep apnea and knee osteoarthritis.

In patients with obesity, retatrutide reduced the severity of sleep apnea by 60.6%.

This disorder interrupts breathing during the night and can increase cardiac risks.

In the case of knee osteoarthritis, the medication reduced pain associated with joint wear by up to 73.1%.

These data can support future regulatory requests to expand the use of the substance.

Illegal market raises alert before approval

Retatrutide still needs to undergo additional safety analyses and formal review by regulatory agencies.

During the presentation at the American Diabetes Association congress, Lilly representatives warned about the illegal circulation of the substance.

In Paraguay, in March of this year, a company announced retatrutide-based pens at an event with Brazilian influencers.

The Federal Revenue states that it has been seizing products brought to Brazil by people crossing the border.

Agents from the Federal Revenue and Anvisa make daily seizures in Foz do Iguaçu.

In the first three months of 2026, the value seized at the border has already surpassed the entire year of 2025, exceeding R$ 11 million.

Currently, any product advertised as retatrutide is illegal in Brazil and has no proven safety.

The advancement of retatrutide can change obesity treatment, but the risk of the parallel market shows that haste can put lives in danger. After all, is it worth trusting a promise sold before official approval?

Sign up
Notify of
guest
0 Comments
most recent
older Most voted
Viviane Alves

Writer specializing in the production of strategic content covering macro and microeconomics, geopolitics, the energy market, the automotive sector, and global trade.

Share in apps
0
I'd love to hear your opinion, please comment.x